We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$214M
AUM Growth
+$9.71M
Cap. Flow
-$616K
Cap. Flow %
-0.29%
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36

Top Buys

Rank Stock Value
1
OCCI
OFS Credit Co
OCCI
+$2.05M
2
HYG icon
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
+$1.92M
3
ECC
Eagle Point Credit Company
ECC
+$1.26M
4
APP icon
Applovin
APP
+$1.04M
5
CEG icon
Constellation Energy
CEG
+$1.01M

Top Sells

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$1.49M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.06M
3
GEN icon
Gen Digital
GEN
+$1.01M
4
ADBE icon
Adobe
ADBE
+$989K
5
STE icon
Steris
STE
+$907K

Sector Composition

Rank Sector Weight
1 Financials 28.16%
2 Healthcare 18.37%
3 Technology 14.33%
4 Industrials 8.16%
5 Consumer Discretionary 6.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
226
Agios Pharmaceuticals
AGIO
$2.14B
$313K 0.15%
7,042
– –
TBPH icon
227
Theravance Biopharma
TBPH
$875M
$309K 0.14%
38,386
– –
GERN icon
228
Geron
GERN
$930M
$306K 0.14%
67,490
– –
DVAX
229
DELISTED
Dynavax Technologies
DVAX
$305K 0.14%
27,423
– –
BBIO icon
230
BridgeBio Pharma
BBIO
$16.8B
$289K 0.14%
11,357
– –
BPMC
231
DELISTED
Blueprint Medicines
BPMC
$286K 0.13%
3,096
– –
LXRX icon
232
Lexicon Pharmaceuticals
LXRX
$1.04B
$283K 0.13%
179,972
– –
NBIX icon
233
Neurocrine Biosciences
NBIX
$18.4B
$278K 0.13%
2,417
– –
NVAX icon
234
Novavax
NVAX
$1.21B
$276K 0.13%
21,884
– –
BMRN icon
235
BioMarin Pharmaceuticals
BMRN
$12B
$275K 0.13%
3,910
– –
BIIB icon
236
Biogen
BIIB
$30.4B
$273K 0.13%
1,408
– –
SWTX
237
DELISTED
SpringWorks Therapeutics
SWTX
$270K 0.13%
8,415
– –
IMCR icon
238
Immunocore
IMCR
$1.7B
$258K 0.12%
8,298
– –
MDGL icon
239
Madrigal Pharmaceuticals
MDGL
$12.4B
$252K 0.12%
1,189
– –
SMMT icon
240
Summit Therapeutics
SMMT
$10B
$249K 0.12%
11,390
+200
+2% +$2.8K
CRSP icon
241
CRISPR Therapeutics
CRSP
$4.68B
$237K 0.11%
5,047
– –
CCOI icon
242
Cogent Communications
CCOI
$649M
$237K 0.11%
3,119
+238
+8% +$16.4K
IRWD icon
243
Ironwood Pharmaceuticals
IRWD
$626M
$227K 0.11%
55,075
– –
APLS
244
DELISTED
Apellis Pharmaceuticals
APLS
$223K 0.1%
7,738
– –
OUT icon
245
Outfront Media
OUT
$5.72B
$223K 0.1%
12,308
+908
+8% +$14.4K
DMC
246
Del Monte Corp
DMC
$1.37B
$219K 0.1%
7,430
+206
+3% +$5.46K
IBRX icon
247
ImmunityBio
IBRX
$7.3B
$209K 0.1%
56,107
– –
ROIC
248
DELISTED
Retail Opportunity Investments Corp.
ROIC
$209K 0.1%
13,266
-947
-7% -$13.8K
SAGE
249
DELISTED
Sage Therapeutics
SAGE
$207K 0.1%
28,639
– –
EPRT icon
250
Essential Properties Realty Trust
EPRT
$6.94B
$206K 0.1%
6,031
-1,068
-15% -$33K
8 9
10
11 12

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, Virtus ETF Advisers held 490 positions worth $214M, up 4.8% from $204M the previous quarter. Its ten largest holdings account for 6.7% of the portfolio.

Virtus ETF Advisers's Q3 2024 filing shows 42 new, 186 increased, 165 reduced and 36 closed positions. Its largest new stake was OFS Credit Co: 278,579 shares worth $2.06M. The largest sale was Oxford Lane Capital, an estimated $1.49M.

By sector, the portfolio is most concentrated in Financials at 28% of assets, up from 27% a quarter earlier, followed by Healthcare and Technology.

  • Virtus ETF Advisers's largest Q3 2024 buy was OFS Credit Co: 278,579 shares worth $2.06M.
  • Virtus ETF Advisers added most to Public Storage in Q3 2024, an estimated $927K increase.
  • Virtus ETF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.06M.
  • Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2024, selling an estimated $1.49M.
  • Virtus ETF Advisers's ten largest holdings make up 6.7% of its $214M portfolio in Q3 2024.
  • Virtus ETF Advisers opened 42 new positions and closed 36 in Q3 2024.
  • Virtus ETF Advisers's portfolio value rose 4.8% quarter-over-quarter to $214M.

Based on Virtus ETF Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.